For example, MV-CEA was administered intraperitoneally in a phase I/II trial in 21 patients with platinum- and paclitaxel-refractory ovarian cancer in the peritoneal cavity [76]. The gene discussed is CEACAM5; the disease is ovarian carcinoma.